C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has appointed Stephen Fawell, Ph.D. to its Board of Directors. Dr. Fawell brings nearly 35 years of drug discovery experience, particularly in oncology. He recently served as vice president of oncology small molecule drug discovery at AstraZeneca, where he advanced over 25 new drugs into clinical trials and supported the development of several approved medications.
Concurrently, Malcolm Salter is retiring from the Board after nearly a decade of service. The company's CEO, Andrew Hirsch, expressed excitement about leveraging Dr. Fawell's expertise in drug discovery and development, aligning with C4 Therapeutics' focus on developing degrader medicines. Dr. Fawell stated his enthusiasm for joining the board and supporting the management team in advancing their portfolio towards pivotal milestones.
C4 Therapeutics (Nasdaq: CCCC), una compagnia biofarmaceutica in fase clinica focalizzata sulla degradazione mirata delle proteine, ha nominato Stephen Fawell, Ph.D. nel suo Consiglio di Amministrazione. Il Dott. Fawell porta con sé quasi 35 anni di esperienza nella scoperta di farmaci, in particolare in oncologia. Recentemente ha ricoperto il ruolo di vicepresidente per la scoperta di farmaci oncologici a piccole molecole presso AstraZeneca, dove ha portato oltre 25 nuovi farmaci in sperimentazione clinica e ha supportato lo sviluppo di diversi farmaci approvati.
Contemporaneamente, Malcolm Salter si ritira dal Consiglio dopo quasi un decennio di servizio. Il CEO dell'azienda, Andrew Hirsch, ha espresso entusiasmo nel poter sfruttare l'expertise del Dott. Fawell nella scoperta e nello sviluppo di farmaci, in linea con l'obiettivo di C4 Therapeutics di sviluppare medicinali degrader. Il Dott. Fawell ha dichiarato il suo entusiasmo per unirsi al consiglio e supportare il team di gestione nell'avanzare il loro portafoglio verso traguardi cruciali.
C4 Therapeutics (Nasdaq: CCCC), una empresa biofarmacéutica en etapa clínica centrada en la degradación selectiva de proteínas, ha designado a Stephen Fawell, Ph.D. en su Junta Directiva. El Dr. Fawell aporta casi 35 años de experiencia en el descubrimiento de medicamentos, especialmente en oncología. Recientemente se desempeñó como vicepresidente de descubrimiento de fármacos oncológicos en AstraZeneca, donde introdujo más de 25 nuevos medicamentos en ensayos clínicos y apoyó el desarrollo de varios medicamentos aprobados.
Al mismo tiempo, Malcolm Salter se retira de la Junta después de casi una década de servicio. El CEO de la compañía, Andrew Hirsch, expresó su entusiasmo por aprovechar la experiencia del Dr. Fawell en el descubrimiento y desarrollo de medicamentos, alineándose con el enfoque de C4 Therapeutics en desarrollar medicamentos degradadores. El Dr. Fawell manifestó su entusiasmo por unirse a la junta y apoyar al equipo de gestión en avanzar hacia hitos fundamentales.
C4 Therapeutics (Nasdaq: CCCC)는 표적 단백질 분해에 집중하는 임상 단계의 생명공학 회사로, Stephen Fawell, Ph.D.를 이사회의 일원으로 임명했습니다. Fawell 박사는 특히 종양학 분야에서 거의 35년의 약물 발견 경험을 가지고 있습니다. 그는 최근 AstraZeneca에서 종양학 소분자 약물 발견의 부사장으로 재직하며 25개 이상의 신약을 임상 시험으로 진입시키고 여러 승인된 약물 개발을 지원했습니다.
동시에, Malcolm Salter는 거의 10년의 서비스 끝에 이사회에서 은퇴합니다. 회사의 CEO인 Andrew Hirsch는 Fawell 박사의 약물 발견 및 개발 전문 지식을 활용하는 것에 대해 흥분을 표했으며, 이는 C4 Therapeutics의 분해 약물 개발에 대한 집중과 일치합니다. Fawell 박사는 이사회에 합류하고 관리팀이 주요 이정표를 향해 나아가는 것을 지원하는 것에 대한 열정을 나타냈습니다.
C4 Therapeutics (Nasdaq: CCCC), une entreprise biopharmaceutique en phase clinique axée sur la dégradation ciblée des protéines, a nommé Stephen Fawell, Ph.D. à son conseil d'administration. M. Fawell apporte près de 35 ans d'expérience en découverte de médicaments, en particulier en oncologie. Il a récemment été vice-président de la découverte de médicaments à petites molécules en oncologie chez AstraZeneca, où il a fait avancer plus de 25 nouveaux médicaments vers des essais cliniques et a soutenu le développement de plusieurs médicaments approuvés.
Parallèlement, Malcolm Salter prend sa retraite du conseil après près d'une décennie de service. Le PDG de la société, Andrew Hirsch, a exprimé son enthousiasme à l'idée de tirer parti de l'expertise de M. Fawell en matière de découverte et de développement de médicaments, ce qui s'aligne sur l'objectif de C4 Therapeutics de développer des médicaments dégradants. M. Fawell a exprimé son enthousiasme à l'idée de rejoindre le conseil et de soutenir l'équipe de direction dans l'avancement de leur portefeuille vers des jalons cruciaux.
C4 Therapeutics (Nasdaq: CCCC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die gezielte Proteinzerstörung konzentriert, hat Stephen Fawell, Ph.D. in seinen Vorstand berufen. Dr. Fawell bringt fast 35 Jahre Erfahrung in der Arzneimittelentwicklung mit, insbesondere in der Onkologie. Er war kürzlich Vizepräsident für die Entdeckung von kleinen Molekülen in der Onkologie bei AstraZeneca, wo er über 25 neue Medikamente in klinische Studien brachte und die Entwicklung mehrerer zugelassener Medikamente unterstützte.
Zur gleichen Zeit tritt Malcolm Salter nach fast einem Jahrzehnt aus dem Vorstand zurück. Der CEO des Unternehmens, Andrew Hirsch, äußerte seine Begeisterung darüber, das Fachwissen von Dr. Fawell in der Arzneimittelentdeckung und -entwicklung zu nutzen, was mit dem Fokus von C4 Therapeutics auf die Entwicklung von Degrader-Medikamenten übereinstimmt. Dr. Fawell äußerte seine Begeisterung, dem Vorstand beizutreten und das Managementteam bei der Weiterentwicklung ihres Portfolios in Richtung wichtiger Meilensteine zu unterstützen.
- Appointment of Stephen Fawell, Ph.D., an experienced biotechnology leader, to the Board of Directors
- Dr. Fawell brings 35 years of drug discovery experience, including success in advancing drugs to clinical trials and regulatory approval
- Dr. Fawell's expertise aligns with C4 Therapeutics' focus on developing degrader medicines
- Retirement of long-serving board member Malcolm Salter, potentially losing valuable experience and institutional knowledge
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service.
“We are excited to welcome Steve to the Board of Directors and leverage his decades of experience leading discovery strategies for global pharmaceutical companies focused on designing innovative molecules, many of which have successfully moved through clinical development and achieved regulatory approval,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “Steve’s expertise across drug discovery and development closely aligns with our continued evolution and steadfast focus on developing degrader medicines for patients in need.”
Mr. Hirsch continued, “On behalf of the Board of Directors, I would like to thank Malcolm Salter for his contributions to C4 Therapeutics. He has been a valued director since shortly after our founding in 2015 and helped us become a publicly traded company, advance several medicines into the clinic and build a culture that attracts, develops and retains top talent. I have enjoyed working with Malcolm and wish him the best in the future.”
On his appointment, Steve Fawell, Ph.D. said, “I am delighted to join the Board of Directors at C4 Therapeutics after closely following the company’s approach to targeted protein degradation for quite some time. I continue to be impressed by C4 Therapeutics’ ability to design potent and selective degraders that have the potential to directly impact disease.” He added, “Now, as a director, I look forward to supporting the management team as they advance the portfolio toward pivotal milestones and bring molecules designed by C4T’s talented team dedicated to targeted protein degradation to additional patients.”
Dr. Fawell has nearly 35 years of drug discovery experience spanning oncology, virology and other disease areas to successfully advance multiple investigational new drugs into clinical trials and ultimately achieve regulatory approval. Most recently, he spent more than a decade at AstraZeneca as vice president, head of oncology small molecule drug discovery where he successfully transitioned more than 25 new drugs into the clinic; advanced camizestrant, ceralasertib and saruparib into late-stage development; and supported the development or approval of Tagrisso®, Lynparza®, Calquence® and Truqap®. At AstraZeneca, Dr. Fawell also helped build the company’s targeted protein degradation platform. Earlier in his career, Dr. Fawell served as vice president, worldwide franchise discovery head, oncology at Merck where he was responsible for all preclinical efforts for the oncology franchise and managing global discovery collaborations. He previously served as executive director, drug discovery head, oncology at Novartis Institutes for Biomedical Research. Dr. Fawell began his career at Biogen, where he held roles of increasing responsibility over a 15-year tenure. He holds a Doctor of Philosophy in biochemistry from University of Leeds and a Bachelor of Science in applied biology from University of Bradford.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d05f2f58-a9bb-4173-b61b-94682e38fbbc
FAQ
Who is the new board member appointed to C4 Therapeutics (CCCC)?
What is Dr. Fawell's background and experience relevant to C4 Therapeutics (CCCC)?
Who is retiring from the C4 Therapeutics (CCCC) Board of Directors?
How might Dr. Fawell's appointment impact C4 Therapeutics (CCCC)?
